Nu Skin Enterprises Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.4B-20.6% YoYTTM through 30 Jun 2026
Net Income -$216.4MTTM through 30 Jun 2026
Free Cash Flow $10.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 69.4% |
| EBITDA Margin | 2.9% |
| Operating Margin | 6.1% |
| Net Margin | -15.7% |
Returns
19.9%ROE
11.4%ROA
Balance Sheet Health
Debt / Equity0.28x
Current Ratio2.08x
Net Debt-$15.7Mnet cash position
Cash & Equivalents$189.6M
Quality Metrics
Altman Z-Score3.72
Piotroski F-Score4 / 9
FCF Margin0.8%
Rule of 404.4
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $1.5B
Diluted EPS-$4.53TTMFY2025: $3.18
Dividend
$0.12Per share, FY20264.50%Yield-39.8%5-yr growth
Capital Allocation
R&D Spend$10.8M
Capex Intensity2.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Beauty Products | $568.1M | View detailsDriven by ageLOC TruFace and ageLOC LumiSpa cleansers and devices. | |
| Wellness Products | $689.1M | View detailsDriven by ageLOC TRME, LifePak, and Beauty Focus. | |
| Rhyz Companies | $223.6M | View detailsStrategic investment arm consisting of consumer, technology, and manufacturing companies. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.